Probiotics and non-intestinal infectious conditions

被引:47
作者
de Vrese, M [1 ]
Schrezenmeir, J [1 ]
机构
[1] Fed Dairy Res Ctr, Dept Physiol & Biochem Nutr, D-24103 Kiel, Germany
关键词
probiotics; non-intestinal infections;
D O I
10.1079/BJN2002630
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 [营养与食品卫生学];
摘要
Orally ingested probiotic micro-organisms do not exert health effects exclusively in the intestine. Some strains can alleviate or prevent bacterial, fungal or viral infections in other organs by stimulation of the immune system. By preservation or improvement of the barrier function of the intestinal mucosa, they may inhibit translocation of potential pathogens and thus prevent infections of the blood stream and other tissues and organs. Modulation of the intestinal microflora can affect the local microflora of the urogenital tract and possibly of the oral cavity. Finally, some strains of orally ingested bacteria reach target organs like the urogenital tract in a viable state; alternatively they can be applied locally. Despite the infection-preventing properties of probiotic bacteria, lactic acid bacteria have rarely been identified in infections of the blood stream, heart valves and other organs, usually only in patients with severe disease. It is the general opinion that in most cases the source of infection was the commensal microflora of the intestine or the oral cavity. Until now only one case of infection associated with administration of a probiotic strain has been published. The most promising health-promoting effects have been seen in vaginosis, urinary tract infections, Helicobacter pylori gastritis and infections of the respiratory tract in children. More controlled clinical trials with sufficient numbers of participants are needed to determine the scientific basis for the use of probiotic bacteria in infections in locations of the body other than the intestine.
引用
收藏
页码:S59 / S66
页数:8
相关论文
共 50 条
[1]
Safety of industrial lactic acid bacteria [J].
Adams, MR .
JOURNAL OF BIOTECHNOLOGY, 1999, 68 (2-3) :171-178
[2]
LACTIC-ACID BACTERIA AND HUMAN CLINICAL INFECTION [J].
AGUIRRE, M ;
COLLINS, MD .
JOURNAL OF APPLIED BACTERIOLOGY, 1993, 75 (02) :95-107
[3]
Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection [J].
Asahara, T ;
Nomoto, K ;
Watanuki, M ;
Yokokura, T .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1751-1760
[4]
Enhancement of resistance in mice treated with Lactobacillus casei:: Effect on Trichinella spiralis infection [J].
Bautista-Garfias, CR ;
Ixta, O ;
Orduña, M ;
Martínez, F ;
Aguilar, B ;
Cortés, A .
VETERINARY PARASITOLOGY, 1999, 80 (03) :251-260
[5]
BAZZOLI F, 1994, GASTROENTEROLOGY, V106, pA48
[6]
LACTOBACILLUS-ACIDOPHILUS INHIBITS GROWTH OF CAMPYLOBACTER-PYLORI INVITRO [J].
BHATIA, SJ ;
KOCHAR, N ;
ABRAHAM, P ;
NAIR, NG ;
MEHTA, AP .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (10) :2328-2330
[7]
BRASSART D, 1993, 1 WORLD C DAIR PROD
[8]
SIGNIFICANT RECOVERY OF NONSPORULATING ANAEROBIC RODS FROM CLINICAL SPECIMENS [J].
BROOK, I ;
FRAZIER, EH .
CLINICAL INFECTIOUS DISEASES, 1993, 16 (04) :476-480
[9]
In vitro adhesion to enamel and in vivo colonization of tooth surfaces by lactobacilli from a bio-yoghurt [J].
Busscher, HJ ;
Mulder, AFJM ;
van der Mei, HC .
CARIES RESEARCH, 1999, 33 (05) :403-404
[10]
Chimura Tetsuro, 1995, Japanese Journal of Antibiotics, V48, P432